Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Clopamide is a pharmaceutical agent belonging to the class of thiazide-like diuretics, chemically related to chlorothiazide but distinguished by its unique structural modifications that enhance efficacy and duration of action. Its molecular formula is C16H14ClN3O4S2, reflecting a complex arrangement containing chlorine, nitrogen, sulfur, and oxygen atoms essential for its biological activity. The substance is identified by the CAS Registry Number 58-90-4, which serves as its universal unique identifier in chemical databases and regulatory frameworks globally.
Primarily utilized in clinical settings, Clopamide functions as an effective antihypertensive and edema-reducing medication. It acts by inhibiting sodium and chloride reabsorption in the distal convoluted tubules of the kidney, thereby promoting the excretion of water and electrolytes. This mechanism significantly reduces blood volume and peripheral resistance, making it a valuable tool in managing chronic hypertension and conditions associated with fluid retention, such as congestive heart failure or renal dysfunction. Unlike some older diuretics, Clopamide offers a more sustained therapeutic effect with a favorable safety profile regarding metabolic disturbances when used at standard dosages.
The drug is typically administered orally in tablet form, allowing for convenient outpatient management of long-term cardiovascular conditions. While generally well-tolerated, clinicians monitor patients for potential side effects including hypokalemia, hyponatremia, hyperglycemia, and hyperuricemia, particularly in individuals with pre-existing metabolic disorders. Its role in combination therapy with other antihypertensives further underscores its versatility in modern treatment protocols. As with all prescription medications, appropriate patient selection and dosage adjustment based on renal function are critical for optimal outcomes. Ongoing research continues to evaluate its comparative advantages against newer agents, ensuring it remains a relevant option in the evolving landscape of cardiovascular pharmacotherapy.